GRAND PHARMA (00512) Enters the Blue Ocean of RSV Treatment, Self-Developed Nebulized Inhalant Approved for Clinical Trial Targeting a Potential Market in the Hundreds of Millions

date
19:53 19/11/2026
avatar
GMT Eight
This marks another major milestone for the Company in anti-infection within the respiratory and critical care field.
On November 19, GRAND PHARMA (00512), a Hong Kong-listed innovative biopharmaceutical company, announced that its self-developed globally innovative nebulized inhalant GPN01564 for the treatment of respiratory syncytial virus (RSV) has been approved by the National Medical Products Administration to conduct Phase I clinical trials. This marks another major milestone for the company in the anti-infection direction within the respiratory and critical care field, and the news has once again pushed the hot RSV field into the industry spotlight. Public information shows that RSV is one of the main pathogens causing lower respiratory tract infections, and globally there is still no approved specific antiviral treatment for RSV. GPN01564 targets the RSV fusion protein (F protein) and adopts a nebulized inhalation route of administration. Its clinical trial approval signifies that GRAND PHARMA has achieved a major breakthrough in this track of unmet clinical need; at the same time, the company's self-development capabilities will be further validated, and its clinical research pipeline will gain a heavyweight product. Targeting F Protein Combined with Nebulized Inhalation, GPN01564 Directly Addresses the Clinical Treatment Gap in RSV In recent years, respiratory syncytial virus (RSV) infection has become a hot track in the global respiratory infection field. As one of the main pathogens causing lower respiratory tract infections, RSV poses a particularly prominent threat to infants and the elderly. According to statistics, in 2019 there were approximately 33 million cases of acute lower respiratory tract infections (ALRTIs) caused by RSV globally; RSV causes over 3.6 million hospitalizations of children under 5 each year, of which approximately 100,000 result in death. China is one of the countries with the highest number of RSV infection cases globally. In 2019, there were approximately 3.5 million cases of ALRTIs caused by RSV in children under 5 in China, accounting for over 10% of the global total, with 620,000 to 950,000 hospitalizations, accounting for 17% to 24% of the global total, ranking second globally. The enormous disease burden is translating into clear commercialization expectations. According to China Insights Consultancy data, the global RSV drug market size (including therapeutic drugs and preventive drugs) is expected to grow from US$1.8 billion in 2020 to US$12.8 billion in 2030, with a compound annual growth rate of 21.4%; of which RSV drugs for children are expected to reach US$11.7 billion in 2030, accounting for 91.1% of the overall market. Focusing on China, the Chinese RSV drug market is expected to grow from US$5.2 million in 2020 to US$1.5 billion in 2030, with a compound annual growth rate of 75.8%, with pediatric drugs accounting for approximately 89.4%. According to previous estimates by Frost & Sullivan, the market for RSV infant preventive vaccines in China alone already reached RMB360 million in 2024, and the potential market space in 2032 is as high as RMB5.8 billion. The performance of preventive products has already validated this commercialization expectation: the world's first approved RSV preventive long-acting monoclonal antibody product, just two years after launch, has already joined the ranks of blockbuster drugs. However, in stark contrast to the rapid volume growth on the prevention side is the long-term absence on the treatment side. According to the "Expert Consensus on Medical-Preventive Coordination for the Prevention and Treatment of Respiratory Syncytial Virus Infection," there is currently no specific antiviral drug for RSV infection, and clinical practice mainly involves symptomatic supportive treatment such as oxygen therapy and fluid replacement based on individual patient conditions. It can be seen that the clinical needs in the field of RSV infection treatment remain far from being met. The emergence of GPN01564 directly addresses this clinical gap. This product is an RSV fusion protein (F protein) inhibitor with differentiated competitive advantages in target selection and route of administration. The product's targetF proteinis a type I membrane fusion protein. Due to its unique antigenic epitope conformation in the pre-fusion conformation and its ability to efficiently induce neutralizing antibodies, it has become one of the most promising targets in the field of RSV prevention and treatment research. In terms of route of administration, GPN01564 relies on the nebulized inhalation route, requiring no systemic administration. The drug directly targets the lungs, achieving precise and non-invasive drug delivery, which can improve the medication experience and form a distinct clinical advantage in terms of administration compliance. From the perspective of administration method, the nebulized inhalation adopted by GPN01564 already has a mature clinical use foundation in China. Menet data shows that in recent years, the sales scale of inhalants (chemical + biological) at the terminal of Chinese public medical institutions has consistently exceeded RMB20 billion, of which the market share of respiratory system drugs exceeds 80%. For GPN01564, which uses nebulized inhalation as its delivery route, China's mature terminal usage habits will provide practical support for its subsequent clinical and commercialization advancement. It is worth noting that the clinical application potential of GPN01564 has been preliminarily validated in the preclinical research stage. According to the announcement, preclinical research results of GPN01564 show that it has good druggability, safety, and efficacy, which will also provide important evidence-based basis for subsequent clinical development and further enhance the certainty of advancing Phase I clinical research. Product Cluster Builds a Systematic Respiratory Treatment System, Platform-Based Layout Gradually Takes Shape For GRAND PHARMA, the emergence of GPN01564 not only enriches the company's existing product pipeline but also holds important value for improving its integrated treatment layout in the respiratory and critical care segment and consolidating the company's differentiated competitive advantages in this field. As an important product reserve for the anti-infection innovation platform in the respiratory and critical care segment, GPN01564 together with the segment's marketed innovative products builds a synergistic product portfolio, forming a closed-loop management system covering the entire airway and full cycle of the respiratory segment. Specifically, the marketed innovative products in GRAND PHARMA's respiratory and critical care segment already cover multiple links of the airway: the novel compound nasal spray Laiteling targets upper airway inflammation such as allergic rhinitis; the innovative inhaled formulations Enzhuorun and Enmingrun for treating asthma focus on the long-term control of lower airway chronic diseases such as asthma; and GPN01564 fills the gap in RSV-specific antiviral treatment. The rich product pipeline jointly constitutes the synergistic portfolio of "full airway, full cycle management" in the respiratory segment, driving the platform's upgrade from a cluster of airway chronic disease products to a systematic respiratory treatment system. It is understood that respiratory and critical care is one of GRAND PHARMA's core strategic areas. The company's marketed products cover multiple indications including rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease, including several products in the medical insurance catalog. It is worth noting that Laiteling was included for the first time in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)" this year, while Enzhuorun and Enmingrun successfully renewed their listing in the national medical insurance drug catalog, which will help improve patient medication accessibility and accelerate market penetration. Leveraging its product and commercialization accumulation in the respiratory and critical care track, GRAND PHARMA has simultaneously laid out an anti-infection innovation pipeline, and GPN01564 is precisely a key candidate variety being advanced in this direction, independently developed by the company relying on its self-built anti-infection innovation platform. According to the company's announcement, this innovation platform is centered on the Wuhan Optics Valley International R&D Center, building a global anti-infection innovative R&D network covering the entire chain from "early discoveryprocess developmentclinical translation." The R&D center covers an area of over 13,000 square meters and is equipped with internationally advanced scientific research equipment, capable of conducting research and development of small molecule drugs, peptide drugs, and high-end complex formulation drugs, and has established specialized laboratories for new drug pharmacodynamic evaluation, process thermal safety evaluation, crystallization technology, and continuous flow process research. The platform holds qualifications including a National Enterprise Technology Center and provincial-level or above R&D innovation technology platforms, and has established a National Postdoctoral Research Workstation. Currently, the platform has laid out high-burden tracks including RSV, sepsis, acute respiratory distress syndrome (ARDS), influenza, herpes virus, novel coronavirus infection, and Gram-negative bacteria, directly addressing unmet clinical needs, forming a continuous project echelon from candidate molecule discovery, preclinical research, regulatory submission to clinical development stages, and is advancing in an orderly manner. Looking ahead, GRAND PHARMA stated that the company will continue to strengthen strategic investment in the platform, focusing on enhancing the level of original innovation, molecular discovery efficiency, and clinical translation capabilities, accelerating the platform's upgrade toward a systematic treatment system, comprehensively supporting the long-term high-quality development of the anti-infection field in the respiratory and critical care segment, and providing more advanced and diverse treatment options for patients worldwide.